MX2013004137A - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX2013004137A
MX2013004137A MX2013004137A MX2013004137A MX2013004137A MX 2013004137 A MX2013004137 A MX 2013004137A MX 2013004137 A MX2013004137 A MX 2013004137A MX 2013004137 A MX2013004137 A MX 2013004137A MX 2013004137 A MX2013004137 A MX 2013004137A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
indacaterol
ciclesonide
beta2
formoterol
Prior art date
Application number
MX2013004137A
Other languages
English (en)
Spanish (es)
Inventor
Geena Malhotra
Shrinivas Madhukar Purandare
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of MX2013004137A publication Critical patent/MX2013004137A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2013004137A 2010-10-12 2011-07-25 Composicion farmaceutica. MX2013004137A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN2847MU2010 2010-10-12
IN69MU2011 2011-01-10
IN106MU2011 2011-01-12
IN135MU2011 2011-01-14
IN143MU2011 2011-01-17
PCT/GB2011/001115 WO2012049444A1 (en) 2010-10-12 2011-07-25 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
MX2013004137A true MX2013004137A (es) 2013-07-29

Family

ID=44651863

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004137A MX2013004137A (es) 2010-10-12 2011-07-25 Composicion farmaceutica.

Country Status (12)

Country Link
US (1) US10179139B2 (enExample)
EP (1) EP2627325A1 (enExample)
JP (2) JP2013542940A (enExample)
KR (2) KR20180028563A (enExample)
CN (2) CN103269694A (enExample)
AU (1) AU2011315315B2 (enExample)
BR (1) BR112013008974A2 (enExample)
CA (1) CA2814445A1 (enExample)
MX (1) MX2013004137A (enExample)
NZ (1) NZ609358A (enExample)
RU (1) RU2642624C2 (enExample)
WO (1) WO2012049444A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105412122A (zh) 2010-07-16 2016-03-23 希普拉有限公司 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物
EP2627325A1 (en) 2010-10-12 2013-08-21 Cipla Limited Pharmaceutical composition
CN103784420A (zh) * 2014-02-18 2014-05-14 青岛市城阳区人民医院 马来酸茚达特罗液体制剂及其制备方法
EP3174522A1 (en) 2014-07-29 2017-06-07 3M Innovative Properties Company Method of preparing a pharmaceutical composition
KR102356120B1 (ko) * 2015-05-01 2022-01-28 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 다중 약물 취성 매트릭스 조성물
CN107995861A (zh) * 2015-05-18 2018-05-04 格兰马克专业公司 用于雾化的泰乌托品吸入溶液
PH12019500577B1 (en) * 2016-09-19 2023-09-08 Mexichem Fluor Sa De Cv Pharmaceutical composition
EP3922240B1 (en) * 2016-09-19 2023-06-21 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising tiotropium bromide
GB2554090A (en) * 2016-09-19 2018-03-28 Mexichem Fluor Sa De Cv Pharmaceutical compound
TR201712424A2 (tr) * 2017-08-21 2019-03-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Kuru toz i̇nhalasyon bi̇leşi̇mleri̇
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
EP3745236A4 (en) 2018-01-24 2021-03-24 Sony Corporation INFORMATION PROCESSING DEVICE AND INFORMATION PROCESSING METHOD
MA52756A (fr) * 2018-06-04 2021-04-14 Lupin Inc Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression
US20200163955A1 (en) * 2018-11-22 2020-05-28 Glenmark Specialty S.A. Sterile compositions of indacaterol suitable for nebulization
US20200215051A1 (en) * 2019-01-03 2020-07-09 Glenmark Specialty S.A. Nebulization composition comprising tiotropium and indacaterol
CN113853197B (zh) * 2019-10-11 2022-08-30 四川海思科制药有限公司 一种吸入溶液药物组合物及其制备方法
CN110840864B (zh) * 2019-12-20 2022-02-22 广州健康元呼吸药物工程技术有限公司 一种β2受体激动剂吸入气雾剂及包含该吸入气雾剂的产品
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
CA3179014A1 (en) * 2020-09-29 2022-04-07 iPharma Labs, Inc. Liquid formulations of indacaterol
AU2023372051B2 (en) * 2022-11-03 2025-12-04 Dana-Farber Cancer Institute, Inc. Methods of treating anemia using formoterol or a pharmaceutically acceptable salt thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
US5879715A (en) 1997-09-02 1999-03-09 Ceramem Corporation Process and system for production of inorganic nanoparticles
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0009591D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medical combinations
CA2405205C (en) 2000-04-28 2007-11-20 Tanabe Seiyaku Co., Ltd. Method for preparing microspheres
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
GB0029562D0 (en) 2000-12-04 2001-01-17 Novartis Ag Organic compounds
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
EP1471895B2 (en) 2002-02-04 2012-03-14 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
CA2496699C (en) * 2002-08-29 2012-07-17 Cipla Ltd. Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
AU2003263717A1 (en) 2002-09-25 2004-04-19 Astrazeneca Ab A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
RS51707B (sr) 2002-12-12 2011-10-31 Nycomed Gmbh. Kombinacija leka sastavljena od r, r - formoterola i ciklezonida
US6962006B2 (en) 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
EP1635845A1 (en) 2003-06-13 2006-03-22 ALTANA Pharma AG Formoterol and ciclesonide combination
SE527190C2 (sv) 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
SE527200C2 (sv) 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
WO2005053851A1 (en) 2003-11-26 2005-06-16 E.I. Dupont De Nemours And Company High pressure media milling system and process of milling particles
US20060008498A1 (en) 2004-07-12 2006-01-12 Chen Tzer-Fen D Nano-particle production
DE102004056578A1 (de) 2004-11-23 2006-05-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum, Formoterol und ein Steroid
CN101102740A (zh) 2005-01-07 2008-01-09 卫材R&D管理有限公司 药用组合物以及其制备方法
EP2484382A1 (en) 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
PL2098248T3 (pl) 2005-12-21 2012-11-30 Meda Pharma Gmbh & Co Kg Kombinacja antycholinergików, glukokortykoidów i beta2-agonistów do leczenia chorób zapalnych
WO2008064357A2 (en) 2006-11-22 2008-05-29 University Of Florida Research Foundation, Inc. Nanoparticles for protection of cells from oxidative stress
EP2327403A3 (en) 2007-02-19 2011-08-31 Cipla Limited Pharmaceutical combinations of at least two bronchodilators
TWI405590B (zh) 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
JP5109515B2 (ja) 2007-07-17 2012-12-26 株式会社ジェイテクト 摺動式トリポード形等速ジョイント
JP2010539182A (ja) * 2007-09-12 2010-12-16 グラクソ グループ リミテッド 治療剤の新規組み合わせ
DE102007054885A1 (de) 2007-11-15 2009-05-20 Evonik Degussa Gmbh Verfahren zur Fraktionierung oxidischer Nanopartikel durch Querstrom-Membranfiltration
FR2929136B1 (fr) 2008-03-25 2011-11-11 Sprainnov Procede et tete de pulverisation, procede et tour associes pour fabriquer un produit pulverulent
BRPI0915803A2 (pt) * 2008-07-18 2015-11-10 Prosonix Ltd processo para aumentar a cristalinidade de pelo menos um material sólido, partícula, composição farmacêutica, e, inalador
CN101474191B (zh) 2009-01-21 2011-03-23 李虎山 一种治疗哮喘和慢性阻塞性肺病的药物组合物
US8668901B2 (en) * 2009-02-04 2014-03-11 Activaero Gmbh Research & Development Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma
EP2221048A1 (en) * 2009-02-18 2010-08-25 Siegfried Generics International AG Pharmaceutical composition for inhalation
EA201171282A1 (ru) 2009-04-24 2012-05-30 Айсьютика Пти Лтд. Способ производства коммерческих порошков, содержащих нано- и микрочастицы
GB0918431D0 (en) 2009-10-21 2009-12-09 Prosonix Ltd Process for improving crystallinity
EP2627325A1 (en) 2010-10-12 2013-08-21 Cipla Limited Pharmaceutical composition

Also Published As

Publication number Publication date
WO2012049444A1 (en) 2012-04-19
NZ609358A (en) 2015-04-24
AU2011315315A1 (en) 2013-05-09
CN103269694A (zh) 2013-08-28
EP2627325A1 (en) 2013-08-21
KR20140025308A (ko) 2014-03-04
US10179139B2 (en) 2019-01-15
KR20180028563A (ko) 2018-03-16
RU2013119938A (ru) 2014-11-20
JP2013542940A (ja) 2013-11-28
AU2011315315B2 (en) 2016-08-18
BR112013008974A2 (pt) 2023-12-19
RU2642624C2 (ru) 2018-01-25
CN107998109A (zh) 2018-05-08
CA2814445A1 (en) 2012-04-19
US20140147393A1 (en) 2014-05-29
JP2017039746A (ja) 2017-02-23

Similar Documents

Publication Publication Date Title
MX2013004137A (es) Composicion farmaceutica.
HUS2000016I1 (hu) Drospirenont és fogamzásgátló kitet tartalmazó gyógyászati készítmény
WO2012007729A3 (en) Pharmaceutical compositions comprising r (+) budesonide and one or more bronchodilators
ZA201307994B (en) Dose counters for inhalers, inhalers and shafts thereof
PL2863950T3 (pl) Aminotriazolopirydyna do zastosowania w leczeniu zapalenia i jej kompozycje farmaceutyczne
PL2688572T3 (pl) Kompozycja farmaceutyczna zawierająca inhibitor hdac i steroid oraz jej stosowanie
SI2739615T1 (sl) Fenil-3-aza-biciklo(3.1.0)heks-3-il-metanoni in njihova uporaba kot zdravilo
ZA201209595B (en) N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament
ZA201509290B (en) Dose counters for inhalers,inhalers and shafts thereof
GEP201706739B (en) Compositions comprising vortioxetine and donepezil
HUE045625T2 (hu) Gyógyászati kompozíciók sebek védelmére, vérpangás szolgáltatására, vagy összetapadás megakadályozására a gyomor- és bél traktusban
IL222707B (en) Steroid compounds of 16-chloro- and 16, 16-dichloro-(4-alpha, 4-beta)-17-beta-(2-oxo-2h-pyran-5-yl) and pharmaceutical preparations containing them
WO2014122460A3 (en) Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
HK1212917A1 (zh) 含硫酸特布他林的剂型
ZA201508249B (en) A pharmaceutical composition containing budesonide and formoterol.
MX2013010947A (es) Complejos de galio, composiciones farmacéuticas y métodos de uso.
WO2010150098A3 (en) Use of quingolide in the treatment of endometriosis, pain and cancer
IN2013MU03370A (enExample)
IL220422A0 (en) Parenteral pharmaceutical formulation in suspension, having sustained release, in low and ultralow dosage, in hormonal therapy in the climacteric syndrome
TN2011000352A1 (en) New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative
IN2013MU02015A (enExample)
PL2852385T3 (pl) Dronedaron do zastosowania w leiszmaniozie, formulacje i połączenia do stosowania w leiszmaniozie
ZA201209743B (en) Pharmaceutical composition comprising drospirenone and contraceptive kit
申美花 The Historic Study of Morphology in Korean
苗曙光 Conflict Management in the Application of Project Cost Management